ERBB2 and breast cancer: More recently, the phase 3 DESTINY-Breast02 study (DB02), which compared the efficacy of T-DXd versus investigator’s choice therapy in patients with metastatic or unresectable HER2+ BC, after T-DM1, showed statistically significant results for PFS and OS in the T-DXd treatment group [13].